6-hydroxy-2,5-dimethyl-3-pyridazinone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-hydroxy-2,5-dimethyl-3-pyridazinone
• 英文别名: 6-hydroxy-2,5-dimethylpyridazin-3-one；2,5-dimethyl-1H-pyridazine-3,6-dione
• 化学式: C₆H₈N₂O₂
• 分子量: 140.142
• InChiKey: QPIATWQGJJHOEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,5-Dimethyl-3-(2H)-pyridazinon-1-oxid 以23%的产率得到
  参考文献：
  名称：

  TSUCHIYA T.; ARAI H.; HASEBE M.; IGETA H., CHEM. AND PHARM. BULL. , 1974, 22, NO 10, 2301-2305

  摘要：

  DOI：

文献信息

• [EN] BICYCLIC FUSED PYRIDINE COMPOUNDS AS INHIBITORS OF TAM KINASES<br/>[FR] COMPOSÉS DE PYRIDINE BICYCLIQUES FUSIONNÉS UTILISÉS EN TANT QU'INHIBITEURS DE KINASES TAM
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2019113190A1

  公开（公告）日：2019-06-13

  Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein Ring A, X1, X2, X3, R1, R2 and R3 are as defined herein, which are inhibitors of one or more TAM kinases and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor.

  本文提供了Formula (I)的化合物及其立体异构体、互变异构体和药用可接受的盐，其中环A、X1、X2、X3、R1、R2和R3如本文所定义，这些化合物是一种或多种TAM激酶的抑制剂，并且在治疗和预防可以用TAM激酶抑制剂治疗的疾病中非常有用。
• One-step ring condensation of hydrazine derivatives and cyclic anhydrides
  作者：Anna Katrusiak、Andrzej Katrusiak

  DOI：10.1016/j.molstruc.2014.12.050

  日期：2015.4

  condensation strongly depends on methyl and other substituents in the anhydrides and in hydrazine. The obtained products indicate that the ring condensation is controlled by the molecular strains and steric hindrances between the substituents in anhydrides and pyridazinone products. The condensation of cyclic anhydrides with hydrazines has been reduced to one-step reaction and its yield significantly increased

  摘要 水合肼与柠康酸、2,3-二甲基马来酸酐、琥珀酸和顺式环己烷二甲酸酐在 HCl 水溶液中进行了羟基哒嗪酮和吡咯二酮环缩合反应。哒嗪-环缩合产生这些条件下出乎意料的产物。它们已通过 1 H/ 13 C NMR 和 X 射线衍射鉴定。向五元环和六元环缩合反应的过程很大程度上取决于酸酐和肼中的甲基和其他取代基。所得产物表明环缩合受酸酐和哒嗪酮产物中取代基之间的分子张力和位阻控制。
• Tautomeric variety and methylation of 3,6-dihydroxy-4-methylpyridazine
  作者：Anna Katrusiak、Andrzej Katrusiak

  DOI：10.1016/j.molstruc.2004.02.020

  日期：2004.6

  Abstract The method of exhaustive methylation has been applied for investigating tautomeric stability and its temperature variation of 6-hydroxy-5-methyl-3-pyridazinone ( 1 ) and its N -phenyl derivative ( 2 )—two model compounds chosen for studying tautomeric transformations of pyridazine medicinal drugs, either in the process of their production, or then their activity in the living tissue. The resulting

  摘要 6-羟基-5-甲基-3-哒嗪酮 (1) 及其 N-苯基衍生物 (2) 的互变异构稳定性及其温度变化已被应用穷举甲基化方法研究——这两种被选择用于研究互变异构转化的模型化合物。哒嗪药物，无论是在它们的生产过程中，还是在它们在活组织中的活性。分离得到的 N-甲基化和 O-甲基化产物，并通过 1 H NMR 和 X 射线衍射表征。硫酸二甲酯及其水溶液中 1 和 2 的甲基化主要导致 O-甲基化形式，但升高的温度有利于 N-甲基化。
• HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS
  申请人：Nishino Taito

  公开号：US20120128640A1

  公开（公告）日：2012-05-24

  An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various disorders is provided. An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells containing a compound represented by the formula (I) (wherein X, Y, Z, Ar 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R6 and R 7 are as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof, which can expand hematopoietic stem cells and/or hematopoietic progenitor cells.

  提供一种用于改善基因治疗中将基因转移至造血干细胞以治疗各种疾病的血液干细胞和/或造血祖细胞扩张剂。该扩张剂包含由式(I)表示的化合物（其中X、Y、Z、Ar1、R1、R2、R3、R4、R5、R6和R7如描述中所定义）、该化合物的互变异构体、前药或药学上可接受的盐或其溶剂，能够扩张血液干细胞和/或造血祖细胞。
• Bicyclic fused pyridine compounds as inhibitors of TAM kinases
  申请人：ARRAY BIOPHARMA INC.

  公开号：US11247990B1

  公开（公告）日：2022-02-15

  Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein Ring A, X1, X2, X3, R1, R2 and R3 are as defined herein, which are inhibitors of one or more TAM kinases and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor.

  本文提供了式（I）化合物：及其立体异构体、同系物和药学上可接受的盐，其中环 A、X1、X2、X3、R1、R2 和 R3 如本文所定义，它们是一种或多种 TAM 激酶的抑制剂，可用于治疗和预防可使用 TAM 激酶抑制剂治疗的疾病。